We are excited for the scientific exchange at virtual #AACR20 part II! Surface is presenting 4 posters, including preclinical data from our two lead clinical-stage antibody therapies: SRF617 (targeting CD39) and SRF388 (targeting IL-27). Learn more: https://t.co/Sa81Ux9mUc https://t.co/YKcNHTjIGx